These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38326978)

  • 21. A new topical treatment of atopic dermatitis in pediatric patients based on Ficus carica L. (Fig): A randomized, placebo-controlled clinical trial.
    Abbasi S; Kamalinejad M; Babaie D; Shams S; Sadr Z; Gheysari M; Askari VR; Rakhshandeh H
    Complement Ther Med; 2017 Dec; 35():85-91. PubMed ID: 29154073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
    King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
    Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of an antiallergic drug (Olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis.
    Furukawa H; Takahashi M; Nakamura K; Kaneko F
    J Dermatol Sci; 2004 Dec; 36(3):165-72. PubMed ID: 15541638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months.
    Diepgen TL;
    Pediatr Allergy Immunol; 2002 Aug; 13(4):278-86. PubMed ID: 12390444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin.
    Vestergaard C; Bang K; Gesser B; Yoneyama H; Matsushima K; Larsen CG
    J Invest Dermatol; 2000 Oct; 115(4):640-6. PubMed ID: 10998136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of autophagy-enhancing peptide in moisturizer on atopic dermatitis: a randomized controlled trial.
    Kwon SH; Lim CJ; Jung J; Kim HJ; Park K; Shin JW; Huh CH; Park KC; Na JI
    J Dermatolog Treat; 2019 Sep; 30(6):558-564. PubMed ID: 30427231
    [No Abstract]   [Full Text] [Related]  

  • 27. Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis.
    Hulshof L; Overbeek SA; Wyllie AL; Chu MLJN; Bogaert D; de Jager W; Knippels LMJ; Sanders EAM; van Aalderen WMC; Garssen J; Van't Land B; Sprikkelman AB;
    Front Immunol; 2018; 9():630. PubMed ID: 29966024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring the efficacy and safety of topical Jaungo application in patients with atopic dermatitis: A pilot randomized, double-blind, placebo-controlled study.
    Ahn JH; Yun Y; Kim MH; Ko SG; Kim KS; Choi I
    Complement Ther Med; 2018 Oct; 40():22-28. PubMed ID: 30219454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
    Silverberg JI; Wollenberg A; Reich A; Thaçi D; Legat FJ; Papp KA; Stein Gold L; Bouaziz JD; Pink AE; Carrascosa JM; Rewerska B; Szepietowski JC; Krasowska D; Havlíčková B; Kalowska M; Magnolo N; Pauser S; Nami N; Sauder MB; Jain V; Padlewska K; Cheong SY; Fleuranceau Morel P; Ulianov L; Piketty C;
    Lancet; 2024 Aug; 404(10451):445-460. PubMed ID: 39067461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation.
    Breternitz M; Kowatzki D; Langenauer M; Elsner P; Fluhr JW
    Skin Pharmacol Physiol; 2008; 21(1):39-45. PubMed ID: 18025807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of topical virgin coconut oil on SCORAD index, transepidermal water loss, and skin capacitance in mild to moderate pediatric atopic dermatitis: a randomized, double-blind, clinical trial.
    Evangelista MT; Abad-Casintahan F; Lopez-Villafuerte L
    Int J Dermatol; 2014 Jan; 53(1):100-8. PubMed ID: 24320105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between serum thymus and activation-regulated chemokine levels and stratum corneum barrier function in healthy individuals and patients with mild atopic dermatitis.
    Furue M; Matsumoto T; Yamamoto T; Takeuchi S; Esaki H; Chiba T; Yamaguchi H
    J Dermatol Sci; 2012 Apr; 66(1):60-3. PubMed ID: 22391243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.
    Oldhoff JM; Darsow U; Werfel T; Katzer K; Wulf A; Laifaoui J; Hijnen DJ; Plötz S; Knol EF; Kapp A; Bruijnzeel-Koomen CA; Ring J; de Bruin-Weller MS
    Allergy; 2005 May; 60(5):693-6. PubMed ID: 15813818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial.
    Simpson EL; Parnes JR; She D; Crouch S; Rees W; Mo M; van der Merwe R
    J Am Acad Dermatol; 2019 Apr; 80(4):1013-1021. PubMed ID: 30550828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of the histamine H
    Werfel T; Layton G; Yeadon M; Whitlock L; Osterloh I; Jimenez P; Liu W; Lynch V; Asher A; Tsianakas A; Purkins L
    J Allergy Clin Immunol; 2019 May; 143(5):1830-1837.e4. PubMed ID: 30414855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ectoine-containing cream in the treatment of mild to moderate atopic dermatitis: a randomised, comparator-controlled, intra-individual double-blind, multi-center trial.
    Marini A; Reinelt K; Krutmann J; Bilstein A
    Skin Pharmacol Physiol; 2014; 27(2):57-65. PubMed ID: 23949258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescents, and Adult Subjects (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis.
    Jacobson ME; Myles IA; Paller AS; Eichenfield LF; Simpson EL
    Dermatology; 2024; 240(1):85-94. PubMed ID: 37579728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial.
    Stainer R; Matthews S; Arshad SH; McDonald S; Robinson J; Schapira C; Foote KD; Baird-Snell M; Gregory T; Pollock I; Stevens MT; Edwards AM
    Br J Dermatol; 2005 Feb; 152(2):334-41. PubMed ID: 15727648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitory effect of 5,6-dihydroergosteol-glucoside on atopic dermatitis-like skin lesions via suppression of NF-κB and STAT activation.
    Jung M; Lee TH; Oh HJ; Kim H; Son Y; Lee EH; Kim J
    J Dermatol Sci; 2015 Sep; 79(3):252-61. PubMed ID: 26100037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.